Dr. Mostafa Norizadeh Tazehkand from Iran (Mioandoab-Qushachay) is currently working as an Assistant Professor in Pharmaceutical Biotechnology department, Bulent Ecevit University, Zonguldak, Turkey. He completed his B.Sc. in Molecular and Cell Biology at Tonekabon University, Iran. Later in 2012, he graduated with M.Sc. in Biotechnology at Cukurova University, Turkey. Dr. Mostafa did his PhD. in Biotechnology at Cukurova University, Turkey in the year 2016. He has published several papers (More than 30) in reputed journals and has participated in several international conferences. He is working as an editorial member in almost 35 scientific journals. His research interests include Vaccine production, Recombinant protein production, Study of cancer, Study of gene expression, Cloning, Study of chromosomal and genetic abnormalities.

Vaccine production, Recombinant protein production, Study of cancer, Study of gene expression, Study of chromosomal and genetic abnormalities.

Dr Joël Richard is currently Senior Vice President, Peptides in IPSEN (France). He is globally leading all the pharmaceutical development activities of both injectable and oral peptide-based products, including APIs and drug products, with major franchises in Oncology, Endocrinology and Neurology. Dr Richard has more than 25 years of experience in chemistry and biopharmaceutical R&D, including several previous global senior positions in various Biotech and Pharma companies, such as: - Vice President, Drug Product Development in Ipsen (France) (2008-2011), - Director, Pharmaceutical Development in Serono and Merck Serono (Italy, Germany) (2005-2008), - Vice President Research, and Europe R&D Director at Ethypharm (France) (2001-2004), - COO at Mainelab (France), a drug delivery company he co-founded, which was specialized in developing solvent-free processes for protein delivery systems (1999-2001). Dr Richard graduated from Ecole Normale Supérieure (Cachan, 1985). He has got a PhD in Materials & Colloidal Science (University of Paris VI, 1987) and “Habilitation à Diriger les Recherches” in Chemistry (University of Bordeaux I, 1994).

In the last 20 years, Dr Richard has focused his research activity on new formulation technologies and drug delivery systems (such as microspheres, nanoparticles, nanocapsules, chemically-modified proteins, supercritical fluid technology . . .), especially for injectable peptide and protein formulations. He has published 67 peer-reviewed scientific papers, 8 book chapters and 2 review editorials in various fields: polymers, colloids and interfaces, drug delivery, biodegradable microspheres, microencapsulation, supercritical fluids, protein formulations and post-translational modifications, nanoparticles, sustained-release formulations. He is the author of more than 120 international communications and 53 patent families.

Prof. Dr. Christopher Brown, Ph.D., D.Sc., CC, AOE, FRS is a Full Professor and Academic Tenure of Chemistry at California South University (CSU), Irvine, California, USA. He is an American analytical and organic chemist, who pioneered a number of discoveries in the field of chemistry, his first and most famous being the synthesis of sucrose. His contributions include the discovery of the anomeric effect and the development of general methodologies for the synthesis of saccharides still employed in the area of Nucleic Acids Chemistry. He was a fellow of the American Chemical Society (ACS) and also the Royal Society of Chemistry (England), and a recipient of the prestigious Albert Einstein World Award of Science and Wolf Prize in Chemistry. Furthermore, he is currently Dean of the Faculty of Chemistry at California South University (CSU), Irvine, California, USA.

Discoveries in the field of chemistry, his first and most famous being the synthesis of sucrose and saccharides

Dr. Dr. Michel Mikhail has more than 25 years Pharmaceutical Industry experience and track record of achievement in R & D and International Regulatory Affairs in large multinational Research-based pharmaceutical Companies, Biotech Companies as well as in the Generic industry. Dr Mikhail is an Expert in Biosimilars. Has been involved in the Global Development and Worldwide regulatory approval of Blockbuster Medicines He was involved in shaping the EU Biosimilars Guidelines and their Review, the WHO Guidelines, Other ICH Guidelines and now in the US-FDA Biosimilars Guidelines. He is a Chartered Expert in Pharmacology -Toxicology, a chartered Clinical Expert as well as a chartered Analytical Expert. Dr Mikhail served on the Safety working group and Efficacy working Group of the European Federation of pharmaceutical Industry associations (EFPIA) also as a Topic leader. He served on the Regulatory Group of the European branch of the Pharmaceutical Research and Manufacturers of America (PhRMA Europe), on the European Biosimilars Group, the Regulatory and Scientific Affairs Group of the European Generic medicines Association (EGA), as well as on different associations and organizations. Dr Mikhail is member of the Expert committee of the Government Federal Institute of Risk Assessment (BfR) Germany. and served as member of the Expert Committee for Toxicology of the United States Pharmacopoeia

Dr. Michel Mikhail’s area of expertise is Non-Clinical Pharmacology and Toxicology as well as Global regulatory Affairs and Regulatory Agencies Interaction. In particular interaction with the US-FDA, the EU_EMA as well as National Agencies in Europe such as UK-MHRA, German BfArM and PEI, France’s ANSM, Sweden’s MPA, among others, interaction with Japan’s PMDA and Emerging markets Agencies. Dr. Michel Mikhail is an Expert in Biosimilars. He is Interested in Immuno-Oncology, Regenerative Medicine, in vitro and in vivo Animal modeling, and mechanisms of Action associated with diseases and regenerative medicine.

Dr. Satinder Ahuja successfully managed development of many new drugs at Novartis Corporation for over 25 years in a number of leadership positions that led to earnings of billions of dollars. His expertise is recognized worldwide in chromatography and separations, especially in the area of ultratrace analyses, chiral separations, and characterization of contaminants by various techniques. As President of Ahuja Consulting, he has advised major pharmaceutical companies in the US and abroad on new drug development and on green chemistry solutions to environmental issues. He has given plenary lectures worldwide, won awards, and published numerous papers and over twenty books.

Ultratrace analyses